United Therapeutics (UTHR) Receivables (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Receivables data on file, last reported at $312.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 3.11% year-over-year to $312.0 million; the trailing twelve-month figure through Mar 2026 stood at $312.0 million (down 3.11% YoY), and the FY2025 full-year result was $350.2 million, up 25.38% from the prior year.
• Receivables eased to $312.0 million in Q1 2026, from $350.2 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $379.3 million in Q2 2025 to a low of $134.5 million in Q1 2023.
• A 5-year average of $271.8 million and a median of $279.3 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables fell 21.11% in 2023 and soared 128.48% in 2024, its largest moves.
• Tracing UTHR's Receivables over 5 years: stood at $220.4 million in 2022, then rose by 26.54% to $278.9 million in 2023, then gained by 0.14% to $279.3 million in 2024, then increased by 25.38% to $350.2 million in 2025, then fell by 10.91% to $312.0 million in 2026.
• Business Quant data shows UTHR's Receivables at $312.0 million in Q1 2026, $350.2 million in Q4 2025, and $297.7 million in Q3 2025.